Mental health
Duloxetine hydrochloride
Brand: Cymbalta
PBAC's latest decision on Duloxetine hydrochloride: Recommended with restriction (2008). Considered for Treatment of major depressive disorder (MDD).
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
2
2007 → 2008
Eligible population
Adults with major depressive disorder treated with duloxetine 60–120 mg daily compared to venlafaxine 75–225 mg daily over 12 weeks.
- Therapy area
- Mental health
- Line of therapy
- Any
- Evidence base
- RCT
- Primary endpoint
- Other
- Pivotal trial size
- 648 patients
- Key trials
- HMBU, HMBQ
- Comparator
- venlafaxine
- Economic model
- Cost-minimisation
- Budget impact
- $10M
- Eligible patients/year
- 200,000
- ICER note
- Cost-minimisation analysis; no ICER calculated.
Submission history
- Jul 2007: Not recommended
- Mar 2008: Recommended with restriction · Restricted
Similar precedents
Open on full dashboard →